Multiple BCR-ABL kinase domain mutations confer polyclonal resistance to the tyrosine kinase inhibitor imatinib (STI571) in chronic phase and blast crisis chronic myeloid leukemiaNeil P. Shah, Charles L. Sawyers, John Nicoll et al.|Cancer Cell|2002Cited by 1.6k
Crystal structures of the kinase domain of c-Abl in complex with the small molecule inhibitors PD173955 and imatinib (STI-571).Bhushan Nagar, John Kuriyan, William G. Bornmann et al.|PubMed|2002Cited by 941
Structural Basis for the Autoinhibition of c-Abl Tyrosine KinaseBhushan Nagar, John Kuriyan, Oliver Hantschel et al.|Cell|2003Cited by 878
Structural Evidence for Feedback Activation by Ras·GTP of the Ras-Specific Nucleotide Exchange Factor SOSS.M. Margarit, John Kuriyan, Brian E. Hall et al.|Cell|2003Cited by 484
A Myristoyl/Phosphotyrosine Switch Regulates c-AblOliver Hantschel, Giulio Superti‐Furga, Bhushan Nagar et al.|Cell|2003Cited by 481